| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Filing example | BLA | — | Subscribe to access the data. | Biologics | Oncology | ||
BLA Filing example | BLA | — | Subscribe to access the data. | Biologics | Oncology | ||
BLA Filing example | BLA | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Candel Therapeutics, Inc.$9.49
-0.4 (-4.05%)
B 64Pipeline Score Undervalued Biotech · Clinical
Market Cap
585.43 M
EPS
-0.98
P/E Ratio
-
Value Trade
18.81 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
9.84 M
Operating CF
-18.04 M
Total Assets
201.92 M
Total Liabilities
63.89 M
Equity
138.03 M
D/E Ratio
12,345
-7.84 %
Week
13.17 %
1 Month
46.61 %
3 Month
79.95 %
6 Month
-0.12 %
5 Year
-0.12 %
All Time
Cash Data
Cash Position
194.83 M
Monthly Burn
6.01 M
Runway
30.7 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
1.19 M
52 Week Range
4.35 - 9.27
% held by Insiders
20.93 %
% held by Institutions
55.09 %
Enterprise Value
439.87 M
Total Shares
54.88 M
Short %
23.51 %
Float Shares
42.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Candel Therapeutics, Inc.
392Total events
9Upcoming
100Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 9
Event history 383
Q3 2026
◆Biomarker Dataaglatimagene besadenovecClinical Data
Biomarker data from prostate program
localized prostate cancersource ↗
Q3 2026
◆Biomarker DataCAN-2409Clinical Data
Immunologic biomarker data from mechanistic clinical trial of CAN-2409 in localized prostate cancer
localized prostate cancersource ↗
Jun 30, 2026
▲Trial Initiationaglatimagene besadenovecTrial
Initiation of global pivotal Phase 3 AURORA trial evaluating aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors
advanced non-small cell lung cancersource ↗
Jun 30, 2026
▲Partnership / LicenseCorporate
Engagement of Parexel International to support global pivotal trial execution
Jun 3, 2026
Jun 2, 2026
▲PublicationCAN-2409Presentation
Publication in The Lancet Oncology of pivotal phase 3 data for CAN-2409 in localized prostate cancer
localized prostate cancersource ↗
Jun 2026
●Trial Initiationaglatimagene besadenovecTrial
Pivotal phase 3 trial initiation in NSCLC planned for June 2026
progressive, metastatic NSCLC despite ICI treatmentsource ↗
May 20, 2026
May 15, 2026
▲Oral Presentationaglatimagene besadenovecPresentation
Extended follow-up data presented at AUA 2026 Annual Meeting
localized prostate cancersource ↗
May 15, 2026
◆Quarterly UpdateCorporate
Investor conference call to discuss extended follow-up data from Phase 3 trial
May 15, 2026
▲Full Resultsaglatimagene besadenovecClinical Data
Extended follow-up data from phase 3 trial with median 58 months follow-up
localized prostate cancersource ↗
Drug Pipeline Intelligence
B64
Pipeline Score $2.8B
Pipeline ValueUndervalued
Valuation Signal4
Drugs Scored4.7x
rNPV / MCap Top 91%
Micro Cap (rank 83 of 911)
Percentile RankCandel Therapeutics, Inc. holds a solid B-grade pipeline (64/100), with $6.9B risk-adjusted pipeline value, led by aglatimagene besadenovec in Prostate Cancer (Phase 3), across $138B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aglatimagene besadenovec Monoclonal antibody | Prostate Cancer | Phase 3 | NCT02768363 | 83% | $5.8B | ACTIVE NOT_RECRUITING | 898 | AVERAGE | B (70) | Dec 1, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
aglatimagene besadenovec Fast TrackRMATOrphan | localized prostate cancer | Phase 3 | 2026-06-02 | 30% improvement in DFS in the aglatimagene arm, compared to placebo (hazard ratio 0.70; 95% confidence interval (CI) 0.52-0.94; p=0.016); 38% improvement in prostate cancer-specific DFS (hazard ratio 0.62; 95% confidence interval 0.44-0.87; p=0.0046); 80% (167/209) of patients in the aglatimagene treatment arm observed with negative biopsies, versus 63% (62/98) observed in the placebo group (p=0.0018) Read More | Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Read More | |
aglatimagene besadenovec Fast TrackRMATOrphan | localized prostate cancer | Phase 3 | 2026-06-02 | 30% improvement in DFS in the aglatimagene arm, compared to placebo (hazard ratio 0.70; 95% confidence interval (CI) 0.52-0.94; p=0.016); 38% improvement in prostate cancer-specific DFS (hazard ratio 0.62; 95% confidence interval 0.44-0.87; p=0.0046); 80% (167/209) of patients in the aglatimagene treatment arm observed with negative biopsies, versus 63% (62/98) observed in the placebo group (p=0.0018) Read More | Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Read More | |
aglatimagene besadenovec Fast TrackRMATOrphan | localized prostate cancer | Phase 3 | 2026-06-02 | 30% improvement in DFS in the aglatimagene arm, compared to placebo (hazard ratio 0.70; 95% confidence interval (CI) 0.52-0.94; p=0.016); 38% improvement in prostate cancer-specific DFS (hazard ratio 0.62; 95% confidence interval 0.44-0.87; p=0.0046); 80% (167/209) of patients in the aglatimagene treatment arm observed with negative biopsies, versus 63% (62/98) observed in the placebo group (p=0.0018) Read More | Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CADL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CADL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CADL▼ -4%today
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics announced the granting of stock options to Mark Sims, the new Chief Commercial Officer, as part of an inducement plan under Nasdaq Listing Rule 5635(c)(4). The options, totaling 285,000 shares at an exercise price of $10.03, will vest over four years. Candel focuses on developing innovative immunotherapies for cancer treatment, with promising clinical trial results for its lead product candidates.
Read more →CADLCandel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics has launched the global pivotal Phase 3 AURORA trial to evaluate aglatimagene besadenovec in combination with valacyclovir and pembrolizumab for patients with advanced non-small cell lung cancer (NSCLC). The trial aims to enroll patients across over 150 sites, focusing on overall survival as the primary endpoint. The initiative builds on promising Phase 2 trial results, addressing a critical need for effective treatments in this patient population.
Read more →CADLCandel Therapeutics Appoints Mark Sims as Chief Commercial Officer
Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer to lead the commercial strategy for aglatimagene besadenovec, aimed at treating localized prostate cancer. The company plans to submit a Biologics License Application in Q4 2026, with a potential launch in 2027. This appointment is part of Candel's strategy to transition into a commercial-stage oncology company.
Read more →CADLCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Candel Therapeutics announced the grant of stock options to three new employees, totaling 63,000 shares at an exercise price of $8.30. This grant is part of the company's 2025 Inducement Plan and aligns with Nasdaq Listing Rule 5635(c)(4). Candel continues to advance its clinical-stage immunotherapies, including successful trials for its lead product candidate, aglatimagene.
Read more →CADLCandel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Candel Therapeutics has published pivotal Phase 3 data in The Lancet Oncology, demonstrating a 30% improvement in disease-free survival for localized prostate cancer patients treated with aglatimagene besadenovec combined with radiotherapy. The study showed no significant increase in toxicity and supports a planned Biologics License Application for aglatimagene in late 2026. The findings highlight the potential of aglatimagene to improve outcomes for patients with high-risk localized prostate cancer.
Read more →CADLCandel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
Candel Therapeutics has reported positive extended follow-up results from its Phase 3 trial of aglatimagene besadenovec in localized prostate cancer. The data showed a 39% improvement in disease-free survival compared to placebo, with significant benefits observed in secondary endpoints. The findings were presented at the AUA 2026 Annual Meeting, reinforcing the potential of aglatimagene to enhance treatment outcomes.
Read more →CADLCandel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Candel Therapeutics reported its Q1 2026 financial results, highlighting plans to submit a Biologics License Application for aglatimagene in prostate cancer by Q4 2026. The company also noted positive extended survival data from NSCLC trials and a strong cash position. A commercial partnership with EVERSANA aims to facilitate the product's U.S. launch.
Read more →CADLForward-looking statements This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contai
Candel Therapeutics presented forward-looking statements regarding their clinical trials and product candidates, specifically focusing on the Phase 3 trial of aglatimagene besadenovec in localized prostate cancer. The data suggest that the combination of aglatimagene besadenovec and prodrug with external beam radiation therapy shows accumulating benefits for patients. However, the projections are subject to various risks and uncertainties, including reliance on third parties and potential discrepancies between forecasts and actual outcomes. The company emphasizes caution in relying on these forward-looking statements, as they carry inherent risks and assumptions.
Read more →CADLCandel Therapeutics to Present at Upcoming Investor Conferences
Candel Therapeutics announced that CEO Paul Peter Tak will present at two upcoming investor conferences. The events include the Stifel 2026 Virtual Targeted Oncology Forum and the 2026 Jefferies Global Healthcare Conference. Candel is focused on developing innovative immunotherapies for cancer and has achieved significant regulatory milestones for its lead product candidates.
Read more →CADL▲ +16.4%on this news
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Candel Therapeutics announced the grant of stock options to two new employees under Nasdaq Listing Rule 5635(c)(4). The options, totaling 29,400 shares at an exercise price of $6.18, are part of the company's 2025 Inducement Plan. Candel is focused on developing multimodal biological immunotherapies for cancer, with ongoing clinical trials for its lead product candidates.
Read more →CADL▲ +16.4%on this newsshared move
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Candel Therapeutics will host a conference call on May 15, 2026, to discuss extended data from the Phase 3 trial of aglatimagene besadenovec in localized prostate cancer. The call follows a presentation at the AUA 2026 Annual Meeting and will include insights from prominent prostate cancer experts. Candel has received FDA designations for its product candidate, enhancing its potential in cancer treatment.
Read more →CADLCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics has granted stock options to two new employees under Nasdaq Listing Rule 5635(c)(4). This grant includes options to purchase a total of 29,400 shares at an exercise price of $6.18. The options will vest over a period of four years, reflecting the company's strategy to attract and retain talent. Candel Therapeutics is focused on advancing its multimodal biological immunotherapies for cancer treatment.
Read more →CADLCandel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Candel Therapeutics has entered a commercialization agreement with EVERSANA to prepare for the potential U.S. launch of aglatimagene besadenovec, aimed at treating intermediate- to high-risk localized prostate cancer. This partnership will enhance Candel's market access capabilities and support various pre-commercialization efforts. Candel's innovative approach allows it to maintain scientific focus while leveraging global commercialization expertise. The planned submission for a Biologics License Application (BLA) is expected in the fourth quarter of 2026, pending regulatory approval.
Read more →CADLCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
Candel Therapeutics announced the grant of stock options to five new employees as part of their 2025 Inducement Plan. The options, totaling 70,000 shares at an exercise price of $4.90, will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's ongoing commitment to developing cancer immunotherapies.
Read more →CADLCandel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics reported promising results from its phase 2a trial of aglatimagene besadenovec (CAN-2409) in patients with advanced non-small cell lung cancer (NSCLC) who previously did not respond to immune checkpoint inhibitors. An extended follow-up revealed that 50% of patients survived beyond 24 months, with significant improvements in overall survival rates. The treatment also demonstrated the ability to enhance immune responses in previously resistant tumors, supporting its potential as a novel therapeutic option.
Read more →CADLCandel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics reported its financial results for Q4 and the full year 2025, highlighting significant progress in its clinical pipeline. The company plans to initiate a pivotal phase 3 trial for aglatimagene in NSCLC in Q2 2026 and submit a BLA for prostate cancer in Q4 2026. Despite a net loss of $29.5 million in Q4 2025, Candel's financial position remains strong with $119.7 million in cash.
Read more →CADLCandel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Candel Therapeutics will present new data from its Phase 3 trial of aglatimagene besadenovec for localized prostate cancer at the AUA 2026 Annual Meeting. The presentation will highlight the accumulating benefits observed in patients treated with CAN-2409 in combination with standard external beam radiation. This significant update will be delivered by Dr. Mark G. Garzotto on May 15, 2026.
Read more →CADLCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026
Candel Therapeutics announced the grant of stock options to a new employee under its 2025 Inducement Plan. The options, totaling 20,000 shares at an exercise price of $5.25, will vest over time. Candel is focused on developing immunotherapies for cancer and has made significant progress with its lead product candidates in clinical trials.
Read more →CADLCandel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
Candel Therapeutics will present at TD Cowen's 46th Annual Health Care Conference in Boston on March 3, 2026. CEO Paul Peter Tak will discuss the company's innovative multimodal biological immunotherapies aimed at treating cancer. Candel's lead candidate, aglatimagene, has shown success in clinical trials and has received various FDA designations.
Read more →CADL▼ -14.2%on this newsshared move
Candel Therapeutics Announces Pricing of Public Offering - February 19, 2026
Candel Therapeutics announced the pricing of a public offering of 18,348,624 shares at $5.45 each, aiming to raise $100 million. The funds will support launch readiness and ongoing clinical trials for its lead product, aglatimagene. The offering is expected to close around February 23, 2026, pending customary conditions.
Read more →CADLCandel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer • RTW committed $100M in U.S. launch fundi
Candel Therapeutics has announced a $100 million royalty funding agreement with RTW Investments to support the launch of Aglatimagene Besadenovec (CAN-2409) for localized prostate cancer, contingent on FDA approval. This non-dilutive funding will help strengthen Candel's balance sheet for commercial preparations, with an expected BLA submission in Q4 of this year. The collaboration reflects strong confidence in the therapy's commercial viability, bolstered by positive results from pivotal phase 3 trials.
Read more →CADLCandel Therapeutics Announces Proposed $100 Million Public Offering
Candel Therapeutics has announced a proposed public offering to raise $100 million, with an option for underwriters to purchase an additional $15 million. The funds raised will be used for launch readiness and ongoing clinical development of their lead product, aglatimagene, which has shown promise in treating early localized prostate cancer and non-small cell lung cancer. The offering's completion is contingent on market conditions, adding an element of uncertainty to the process.
Read more →CADLCandel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
Candel Therapeutics will present at the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026. Dr. Francesca Barone will discuss insights from the company's HSV-based platform and the CAN-3110 program for recurrent high-grade glioma. The summit will include workshops and panel discussions focused on biomarker-driven clinical development.
Read more →CADLCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2026
Candel Therapeutics announced the grant of stock options to a new employee under Nasdaq Listing Rule 5635(c)(4). The options, totaling 6,600 shares at an exercise price of $5.84, will vest over four years. Candel continues to develop its multimodal biological immunotherapies, with promising results from clinical trials for its lead product candidate, aglatimagene.
Read more →CADLRESEARCH & DEVELOPMENT DAY Virtual Event |
Candel Therapeutics recently highlighted its ongoing clinical developments and strategic plans during a Virtual Research & Development Day. The company reported positive survival outcomes from its Phase 2a trials of CAN-2409 in various cancer types and outlined future milestones, including a potential BLA filing. Candel's pipeline, particularly focused on innovative cancer therapies, is backed by substantial financial resources and an experienced leadership team. Additionally, key FDA designations for its therapies indicate favorable regulatory conditions moving forward.
Read more →CADLCandel Therapeutics to Host Virtual R&D Event on December 5, 2025
Candel Therapeutics is set to host a virtual Research and Development event on December 5, 2025, detailing its advancements in multimodal biological immunotherapies. The event will feature presentations from top executives and clinical investigators, focusing on the company's pipeline and innovative approaches to cancer treatment. Key topics will include the progress of their lead candidate, CAN-2409, which aims to enhance anti-tumor immunity. Notably, CAN-3110, another product candidate, is under investigation for recurrent glioblastoma following promising preliminary results.
Read more →CADL▼ -6.3%on this newsshared move
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics reported positive advancements in its clinical pipeline during Q3 2025, including supportive data from a phase 3 trial of CAN-2409 for localized prostate cancer. The company secured a $130 million term loan to support its operations and plans for a BLA submission in Q4 2026. Despite a net loss increase, the company remains optimistic about upcoming trials and data releases.
Read more →CADLCandel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
Candel Therapeutics will present at the SITC 2025, highlighting its advancements in immunotherapy, particularly the CAN-2409 treatment for prostate cancer. The company emphasizes the integration of multi-omics and AI in developing novel therapies. Positive phase 3 clinical trial data supports their approach, with plans for a Biologics License Application in late 2026.
Read more →CADLCandel Therapeutics to Present at Jefferies Global Healthcare Conference in London
Candel Therapeutics announced that its CEO, Paul Peter Tak, will present at the Jefferies Global Healthcare Conference in London from November 17-20, 2025. The company focuses on developing multimodal biological immunotherapies for cancer treatment. Candel's lead product, CAN-2409, has received several FDA designations and completed successful phase 2a trials in various cancers.
Read more →CADL▼ -9.3%on this news
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
Candel Therapeutics has appointed Dr. Bali Pulendran to its Research Advisory Board. Dr. Pulendran, a leading expert in systems immunology, will contribute his knowledge as Candel advances its viral immunotherapy candidates, CAN-2409 and CAN-3110. The company has achieved significant milestones, including successful phase 2a trials and FDA designations for its therapies.
Read more →CADL▼ -10.7%on this newsshared move
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
Candel Therapeutics has entered a $130 million term loan facility with Trinity Capital to bolster its financial position. The funding will primarily support the initiation of a pivotal phase 3 clinical trial for CAN-2409 in non-small cell lung cancer (NSCLC) and prepare for a potential launch in localized prostate cancer. The company also plans to focus resources on these two major oncology indications.
Read more →CADL▼ -10.7%on this newsshared move
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
Candel Therapeutics announced positive interim data from its phase 1b trial of CAN-3110 in recurrent glioblastoma, revealing significant immune responses and improved overall survival rates. The findings were published in Science Translational Medicine, showcasing the potential of CAN-3110 to transform the tumor microenvironment. The company plans to design a phase 2 trial based on these results.
Read more →CADLCandel Therapeutics to Present at the SITC 2025 Annual Meeting
Candel Therapeutics announced its participation in the SITC 2025 Annual Meeting, where it will present insights from its enLIGHTEN™ Discovery Platform and data from the CAN-2409 program targeting non-small cell lung cancer. Notably, Dr. Paul Peter Tak will discuss positive phase 3 trial results for CAN-2409 in localized prostate cancer. The meeting is scheduled for November 5-9, 2025, in National Harbor, Maryland.
Read more →CADLCandel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
Candel Therapeutics presented positive results from its Phase 3 trial of CAN-2409 for localized prostate cancer at ASTRO 2025. The trial showed a 30% improvement in disease-free survival and highlighted the treatment's efficacy across different radiation modalities. This marks a significant advancement in prostate cancer treatment, with a Biologics License Application submission expected in late 2026.
Read more →CADLCandel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
Candel Therapeutics, Inc. announced that an abstract detailing Phase 3 results of its CAN-2409 treatment for localized prostate cancer has been accepted for presentation at the 2025 ASTRO Annual Meeting. The presentation will highlight a clinical trial which achieved its primary endpoint and includes findings from the company's research in other cancer types as well. Further, CAN-2409 has received significant FDA designations, showcasing its potential impact on patients with prostate cancer.
Read more →CADLCandel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
Candel Therapeutics has appointed Dr. Carl H. June to its Research Advisory Board. Dr. June, a pioneer in cancer immunotherapy, will contribute his expertise as Candel advances its lead candidates, CAN-2409 and CAN-3110. The company is focused on developing viral immunotherapies for various cancers and has received significant FDA designations for its products.
Read more →CADLCandel Therapeutics to Participate in Upcoming Investor Conferences in September
Candel Therapeutics, Inc. announced that its CEO, Paul Peter Tak, will participate in several upcoming investor conferences in September 2025. These conferences include the Citi Biopharma Conference and the Cantor Global Healthcare Conference, among others. The participation is expected to enhance investor engagement as the company advances its clinical-stage therapies aimed at treating cancer. Candel's lead product, CAN-2409, has shown promising results in phase 2a trials and has received multiple FDA designations, underscoring its potential in oncology.
Read more →CADL▼ -5.6%on this news
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights • Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimage
Candel Therapeutics announced positive financial results for Q2 2025, highlighted by favorable outcomes from a phase 3 clinical trial of CAN-2409 for localized prostate cancer. The trial demonstrated a 30% improvement in disease-free survival compared to placebo. Additionally, the company received FDA RMAT Designation for CAN-2409 and successfully completed a registered direct offering, securing approximately $15 million in gross proceeds. With multiple regulatory designations and strong clinical data, Candel is well-positioned for its upcoming Biologics License Application (BLA) submission in Q4 2026.
Read more →CADLCandel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
Candel Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Paul Peter Tak, will present at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, on August 13, 2025. The company is focused on developing cancer immunotherapies and has made progress with its lead product candidate, CAN-2409, which has received important FDA designations. Candel's innovative approach to cancer treatment is highlighted by its multimodal biological immunotherapy platforms, which aim to elicit an anti-tumor immune response.
Read more →CADLCandel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Candel Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Designation to CAN-2409 for the treatment of pancreatic cancer, which complements its previous FDA designations. The drug, designed to induce an immune response against tumors via a genetically modified adenovirus, has shown significant survival benefits in clinical trials, particularly for pancreatic ductal adenocarcinoma (PDAC). Candel's leadership emphasizes the transformative potential of CAN-2409 as they work to make this innovative therapy available to patients with limited options.
Read more →CADL▲ +16.2%on this news
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
Candel Therapeutics, Inc. has been added to several Russell indexes, including the Russell 2500 Value® Index and Russell 2000 Value® Index, as part of the 2025 reconstitution. This inclusion, effective from June 30, 2025, highlights Candel's progress in advancing its clinical programs. The company is preparing for the submission of a Biologics License Application for its candidate CAN-2409 in localized prostate cancer, while also engaging with the investment community as it develops novel immunotherapies.
Read more →CADLCandel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
Candel Therapeutics announced a registered direct offering of approximately 3.2 million shares of common stock, raising about $15 million. The offering aims to support pre-commercialization efforts for CAN-2409 in prostate cancer, pending regulatory approval. It involves strategic healthcare-focused investors and highlights confidence in the company's cancer treatment strategies. The funds will also assist in the submission process for a Biologics License Application expected in late 2026.
Read more →CADLCandel Therapeutics Appoints Charles Schoch as Chief Financial Officer Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financ
Candel Therapeutics has officially appointed Charles Schoch as its Chief Financial Officer after his tenure as interim CFO since January 2024. His promotion comes on the back of commendation for his exceptional financial leadership, particularly his role in guiding the company through significant operational and financial challenges. Under his direction, Candel successfully raised approximately $86 million following positive results from a phase 3 clinical trial of their lead therapy, CAN-2409. Schoch's strong background in finance and operations is expected to benefit the company's strategic priorities and clinical advancements.
Read more →CADL▲ +8.8%on this news
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Applica
Candel Therapeutics has appointed Dr. Maha Radhakrishnan to its Board of Directors, effective June 4, 2025. Dr. Radhakrishnan's extensive experience in product development and commercialization is expected to be instrumental as the company prepares for the Biologics License Application submission for its candidate CAN-2409 in prostate cancer. The appointment comes at a critical time as Candel advances its innovative immunotherapy programs aimed at addressing significant unmet needs in cancer treatment.
Read more →CADL▲ +6.1%on this news
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
Candel Therapeutics has received the FDA's Regenerative Medicine Advanced Therapy designation for its lead candidate CAN-2409, aimed at treating newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. This designation is based on promising data from a phase 3 trial that showed significant improvements in disease-free survival compared to placebo. The company anticipates filing a Biologics License Application by the end of 2026, with the goal of offering a new treatment option for patients suffering from this cancer type. The RMAT designation will facilitate further collaboration with the FDA to expedite the development process.
Read more →CADLCandel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
Candel Therapeutics has announced an investor conference call to discuss the positive results from its phase 3 clinical trial of CAN-2409 for localized intermediate-to-high-risk prostate cancer. The results show a significant 30% reduction in disease recurrence compared with placebo when combined with standard radiation therapy. The call, scheduled for June 3, 2025, will feature expert commentary from principal investigators in the trial, and follows a presentation at the 2025 ASCO Annual Meeting. CAN-2409 is Candel's leading candidate and is also being evaluated for other cancer types, including non-small cell lung cancer and pancreatic adenocarcinoma.
Read more →CADLCandel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
Candel Therapeutics has announced positive results from its Phase 3 clinical trial of CAN-2409 for patients with intermediate-to-high-risk localized prostate cancer. The trial met both primary and secondary endpoints, showing a significant improvement in disease-free survival compared to the placebo group. CAN-2409, in combination with standard radiotherapy, reduced the risk of cancer recurrence or death. The study will be presented at the upcoming ASCO Annual Meeting in Chicago, reinforcing Candel's commitment to advancing treatments for prostate cancer.
Read more →CADL▲ +7.7%on this news
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights • Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of C
Candel Therapeutics has reported strong financial results for Q1 2025 and highlighted positive developments in its clinical pipeline, particularly for its lead candidate CAN-2409. The company has noted significant improvements in median overall survival in patients with advanced cancers, including non-small cell lung cancer and borderline resectable pancreatic adenocarcinoma. The promising phase 3 trial in localized prostate cancer has been accepted for presentation at the ASCO Annual Meeting, and a Biologics License Application is anticipated by Q4 2026. Additionally, Candel is focusing on strategic commercial collaborations to optimize the development of CAN-2409.
Read more →CADLCandel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
Candel Therapeutics announced that its phase 3 trial results for CAN-2409 in localized prostate cancer will be presented at the 2025 ASCO Annual Meeting. The trial demonstrated statistically significant improvements in disease-free survival when combined with standard radiation therapy. This oral presentation will be led by Dr. Theodore DeWeese from Johns Hopkins Medicine, highlighting the potential of CAN-2409 as a significant advancement in cancer therapy. Candel's ongoing research includes additional trials in various cancer types, suggesting a robust pipeline for further innovation.
Read more →CADLCandel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Candel Therapeutics announced the publication of positive findings from a Phase 1b clinical trial investigating the safety and efficacy of CAN-2409 in combination with nivolumab and standard care for newly diagnosed high-grade glioma patients. The trial included 41 participants, with a notable subset demonstrating improved overall survival and immune response. Despite the encouraging outcomes, the prognosis for high-grade glioma remains generally poor, highlighting the need for further investigation into effective treatment options.
Read more →CADL▼ -7.3%on this news· ran to -26% by day 3shared move
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpo
Candel Therapeutics announced promising final survival data from a Phase 2a clinical trial of its investigational drug CAN-2409 for advanced non-small cell lung cancer (NSCLC) patients who are resistant to immune checkpoint inhibitors. The study revealed a median overall survival of 24.5 months among participants, significantly exceeding previous benchmarks from standard treatments. Additionally, 37% of patients survived more than 24 months after treatment. The findings suggest that CAN-2409 may offer a new therapeutic avenue for a patient population with limited options.
Read more →CADL▼ -7.3%on this news
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
Candel Therapeutics has announced a strategic partnership with IDEA Pharma to enhance the commercialization of its lead asset, CAN-2409, following encouraging phase 3 clinical trial results in prostate cancer. The collaboration aims to leverage IDEA's expertise in commercialization to support Candel in navigating the market entry process. CAN-2409 has demonstrated significant improvements in disease-free survival and response rates in recent trials. The partnership is expected to run through 2026 and comes at a crucial time as Candel prepares for its BLA submission.
Read more →CADLCandel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
Candel Therapeutics has appointed Dr. Elizabeth M. Jaffee, a noted expert in pancreatic cancer and immunotherapy, to its Research Advisory Board. Dr. Jaffee's role is expected to significantly benefit Candel as the company advances its CAN-2409 program aimed at borderline resectable pancreatic cancer. This appointment comes after Candel reported positive survival results in clinical trials involving CAN-2409. Dr. Jaffee brings extensive experience from her leadership roles at renowned institutions and will guide the design of late-stage clinical trials.
Read more →CADLCandel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights • Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial
Candel Therapeutics reported strong financial results for Q4 and the full year 2024, highlighting significant advancements in its clinical trials. Notable achievements include positive data from pivotal phase 3 trials of CAN-2409 in localized prostate cancer and favorable outcomes from phase 2a trials in pancreatic cancer. The company is on track to submit its Biologics License Application for CAN-2409 and anticipates further progress in ongoing trials for both prostate and non-small cell lung cancers. Overall, Candel is positioned to address substantial unmet needs in oncology through its promising therapies.
Read more →CADL▼ -23.5%on this news
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer • Positive final survival data after additional follow-u
Candel Therapeutics announced positive final survival data from a Phase 2 trial of CAN-2409 in patients with non-metastatic pancreatic cancer. The study showed a median overall survival of 31.4 months for those receiving the treatment, compared to 12.5 months in the control group. Notably, three patients in the treatment group remained alive well beyond standard survival prospects for the disease. The trial indicated a favorable safety profile for CAN-2409, with plans for a larger late-stage trial in this indication.
Read more →CADL▼ -5%on this news
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
Candel Therapeutics announced significant advancements in its clinical pipeline, particularly for CAN-2409, which is under evaluation for prostate cancer, pancreatic cancer, and non-small cell lung cancer. The company is preparing for a Biologics License Application for CAN-2409 in prostate cancer, with data presentations planned for upcoming conferences. Recent results showed promising overall survival rates in multiple indications, and the company anticipates maintaining financial stability through 2027.
Read more →CADL▲ +9.2%on this news
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 • On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in
Candel Therapeutics has provided an optimistic corporate update highlighting its advancements in cancer treatment development, notably with the CAN-2409 pipeline. The company plans to present significant data from various clinical trials and is preparing for a Biologics License Application for CAN-2409 in prostate cancer, aiming for submission by Q4 2026. Anticipated survival data from ongoing clinical trials, including for pancreatic and lung cancers, are expected in early 2025. Candel's robust pipeline and positive results indicate a solid foundation moving forward into 2025.
Read more →CADL▼ -8.8%on this news· ran to +48% by day 3
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Candel Therapeutics has concluded its public offering, successfully selling 12,000,001 shares of common stock at $6.00 per share, alongside pre-funded warrants. This offering secured approximately $92 million in gross proceeds, which Candel plans to utilize for advancing its product candidates, particularly CAN-2409 aimed at treating prostate cancer. The full exercise of the underwriters' option to purchase additional shares demonstrates robust investor confidence in the company's prospects. The offering was managed by a consortium including Citigroup and BofA Securities.
Read more →CADL▼ -31.1%on this newsshared move
Candel Therapeutics Announces Pricing of Public Offering
Candel Therapeutics, Inc. has announced the pricing of a public offering of 10,000,001 shares of common stock at $6.00 per share, along with pre-funded warrants. The company aims to raise approximately $80 million, which will be used primarily for developing its product candidates, particularly the Biologics License Application for CAN-2409 in prostate cancer. The offering is expected to close around December 16, 2024, subject to customary conditions. Citigroup, BofA Securities, and Canaccord Genuity are leading the offering.
Read more →CADL▲ +26.5%on this newsshared move
Candel Therapeutics Announces $80 Million Proposed Public Offering
Candel Therapeutics has announced a public offering of $80 million of its common stock. The funds raised will be allocated towards the development of its cancer immunotherapies, particularly for the submission of a Biologics License Application for CAN-2409 targeted at prostate cancer. The offering is contingent on market conditions and includes a potential additional purchase option for underwriters.
Read more →CADL▲ +68.1%on this newsshared move
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival Positive topline data for CAN-2409 viral immunotherapy, achieved pri
Candel Therapeutics announced that its CAN-2409 viral immunotherapy successfully met its primary endpoint in a Phase 3 trial for localized prostate cancer, showing significantly improved disease-free survival. The trial involved 745 patients and demonstrated a favorable safety profile consistent with prior studies. With potential market value exceeding $10 billion in the U.S., Candel intends to engage with the FDA to seek regulatory approval for CAN-2409. These results could transform treatment paradigms in prostate cancer care.
Read more →CADLCandel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights • On track for topline disease-free survival data from the phase 3 randomized controlled clinical trial of CAN-2409
Candel Therapeutics announced its financial results for Q3 2024, highlighting its progress in developing CAN-2409 for localized prostate cancer and CAN-3110 for recurrent high-grade glioma. The company is on track for securing important clinical data by the end of Q4 2024, while also presenting early promising data on immunotherapy candidates at recent conferences. Despite an increase in net loss and a significant drop in cash reserves, Candel expects to maintain funding through Q1 2025. Overall, the outlook for upcoming clinical data appears optimistic for Candel's therapeutic pipeline.
Read more →CADLCandel Therapeutics to Present at Jefferies London Healthcare Conference 2024
Candel Therapeutics, a biopharmaceutical company focused on cancer immunotherapy, announced that CEO Paul Peter Tak will present at the Jefferies London Healthcare Conference 2024. The presentation is scheduled for November 20, 2024, and will cover the company's innovative multimodal biological immunotherapy platforms. Candel is actively developing treatments for various cancers, with multiple candidates in clinical trials. A webcast of the presentation will be available for investors and stakeholders.
Read more →CADLCandel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Candel Therapeutics announced promising preclinical data for its oncolytic viral immunotherapy candidate, CAN-3110, at the SITC Annual Meeting. The findings demonstrate significant antitumor activity in melanoma models, suggesting that CAN-3110 could extend its therapeutic application beyond recurrent high-grade glioma to include other Nestin-expressing tumors. The data, which shows immune activation and tumor growth inhibition, will be presented by Dr. Anne R. Diers. This development positions CAN-3110 as a potential first-in-class treatment option in a new indication.
Read more →CADLCandel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virus Conference (IOVC)
Candel Therapeutics presented significant findings regarding their innovative cancer therapies at the 16th Annual International Oncolytic Virus Conference. Highlights include new data from their phase 1b trial of CAN-3110, showing improved survival in recurrent high-grade glioma patients. Additionally, a novel multimodal immunotherapy candidate from the enLIGHTEN Discovery Platform was introduced, focusing on enhancing immune activation. The company's pipeline and ongoing clinical trials indicate a commitment to broadening therapeutic options for solid tumors.
Read more →CADLCandel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Candel Therapeutics will present preclinical data on its candidate CAN-3110 for melanoma at the SITC Annual Meeting from November 6-10, 2024. The therapy, designed to target cancers with Ras-Raf pathway alterations, shows potential based on prior clinical findings, including improvements in median overall survival for recurrent high-grade glioma. The results of this presentation will be made publicly available after the event on the company’s website.
Read more →CADL▼ -6.5%on this news
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Candel Therapeutics, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. CEO Paul Peter Tak will lead the presentation, highlighting the company's advancements in developing multimodal biological immunotherapies for cancer treatment. Candel's lead product candidates are currently in various phases of clinical trials targeting non-small cell lung cancer, pancreatic cancer, and prostate cancer, among others. The company aims to share insights on its progress and future plans during this pivotal event.
Read more →CADLCandel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights • Announced positive survival data from the phase 2 randomized controlled clinical trial of CAN-2409 in borderline
Candel Therapeutics has released its Q2 2024 financial results, highlighting positive survival data for its lead candidate CAN-2409 in clinical trials for pancreatic and lung cancers. The company has received orphan drug designation from the FDA for its therapies and is preparing for significant milestones in the near future, including important clinical trial readouts. Despite an increase in net loss, Candel maintains sufficient cash reserves to fund operations through Q1 2025.
Read more →CADL▼ -6.9%on this news· ran to -17% by day 1
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
Candel Therapeutics, Inc. announced participation in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference, featuring CEO Paul Peter Tak. The company focuses on developing multimodal biological immunotherapies aimed at fighting cancer. Candel's lead candidate, CAN-2409, has shown promising clinical data in ongoing trials for non-small cell lung cancer and pancreatic cancer. The company is set to present further updates on its trials in the coming months, which could influence its market standing.
Read more →CADL▲ +7.4%on this news
Candel Therapeutics to Join Russell 3000 Index
Candel Therapeutics, a clinical stage biopharmaceutical company, will join the Russell 3000 Index effective July 1, 2024. This inclusion is indicative of the company's growth and progress in developing cancer immunotherapies. Candel's leadership emphasizes the potential for increased investor visibility and the opportunity to further engage with the financial community as they continue their clinical trials. The Russell 3000 Index is a key benchmark for investment strategies in the U.S. market.
Read more →CADLCandel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 20
Candel Therapeutics announced promising results from a Phase 2 clinical trial of CAN-2409 for patients with advanced non-small cell lung cancer (NSCLC) who did not respond to immune checkpoint inhibitors. The trial demonstrated a median overall survival of 20.6 months after treatment, significantly higher than the 11.6 months observed with standard chemotherapy. The treatment activated an immune response and showed benefits across both injected and uninjected tumors. The findings, to be presented at the 2024 ASCO Annual Meeting, highlight CAN-2409's potential as a new therapeutic option for this difficult-to-treat patient population.
Read more →CADL▼ -13.8%on this news· ran to -30% by day 3shared move
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
Candel Therapeutics, a clinical stage biopharmaceutical company, announced that its President and CEO, Paul Peter Tak, will present at the Jefferies Global Healthcare Conference on June 5, 2024. Candel is dedicated to developing multimodal biological immunotherapies to treat cancer, with several ongoing clinical trials for its lead product candidates, CAN-2409 and CAN-3110. The presentation aims to provide an overview of the company's innovative research and advancements in personalized cancer treatment.
Read more →CADLCandel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
Candel Therapeutics announced it will host a webcasted R&D breakfast panel on June 3, 2024, during the ASCO Annual Meeting. The panel will discuss topline overall survival data from the phase 2 clinical trial of its lead product, CAN-2409, aimed at treating Non-Small Cell Lung Cancer (NSCLC). The event will feature key opinion leaders in the field and aims to highlight the potential of the company's immunotherapy approach. CAN-2409 is under active evaluation for multiple cancer types and has received significant regulatory designations to accelerate its development.
Read more →CADLCandel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights • Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectab
Candel Therapeutics announced its financial results for Q1 2024 and highlighted positive outcomes from its clinical trials. Notable data from a phase 2 trial of CAN-2409 in pancreatic cancer showed significant improvements in overall survival compared to traditional treatments. The FDA awarded CAN-2409 Fast Track and Orphan Drug Designations, fostering further development. However, the company reported a net loss of $8.2 million and a reduced cash position, prompting scrutiny of its financial sustainability moving forward.
Read more →CADL▲ +6.3%on this news· ran to +17% by day 3
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
Candel Therapeutics announced two accepted abstracts for presentation at the 2024 ASCO Annual Meeting scheduled for May 31 to June 4 in Chicago. The presentations will highlight data from their ongoing trials with CAN-3110 for recurrent high-grade glioma and CAN-2409 for non-small cell lung cancer. Preliminary data indicate that CAN-3110 is well tolerated and shows potential in enhancing survival rates, while CAN-2409 demonstrates effectiveness in combination with other therapies for advanced lung cancer. Full abstracts will be available on May 23, 2024.
Read more →CADL▲ +42.7%on this news
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Candel Therapeutics has received FDA Orphan Drug Designation for CAN-2409, an innovative immunotherapy for pancreatic cancer. This designation follows promising phase 2 trials showing significant improvements in overall survival rates when added to standard care. The treatment demonstrates a favorable safety profile, with no dose-limiting toxicities reported. Candel aims to reshape the treatment of pancreatic cancer, a condition with high unmet medical needs.
Read more →CADL▼ -20.8%on this newsshared move
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors • First-in-class multimodal immunotherapy candidate, for induction of
Candel Therapeutics has presented promising preclinical data at the AACR Annual Meeting for its first-in-class multimodal immunotherapy candidate designed to induce tertiary lymphoid structures in solid tumors. Using its enLIGHTEN Discovery Platform, the company demonstrated that unique payload combinations can inhibit tumor growth and enhance responses to existing immune checkpoint therapies. This development not only accelerates the timeline for releasing a second immunotherapy candidate but also underscores the potential of Candel's platform to innovate in cancer treatment strategies. The company's leverage of AI and delivery systems exemplifies a commitment to evolving therapeutic approaches in oncology.
Read more →CADL▲ +281%on this news· ran to +295% by day 1shared move
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer • Updated positive interim data showed notable improvements in estimated m
Candel Therapeutics announced updated interim results from a Phase 2 clinical trial of CAN-2409 in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). The trial showed a remarkable increase in median overall survival, with treated patients experiencing 28.8 months compared to 12.5 months for the control group. Furthermore, survival rates at 24 and 36 months significantly outperformed those of the control. The treatment was generally well tolerated, demonstrating no new safety signals.
Read more →CADLCandel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
Candel Therapeutics has announced updated data from its Phase 1b clinical trial of CAN-3110, a viral immunotherapy for recurrent high-grade glioma (rHGG). The data, presented at the 5th Glioblastoma Drug Development Summit, highlights the promising efficacy of CAN-3110, showing nearly double the expected median overall survival of ~12 months. The initial cohort's multiple injections were well tolerated, and an additional cohort is planned for enrollment. Candel's recent achievements include FDA Fast Track Designation and a publication of results in Nature, which aim to enhance the future development of CAN-3110.
Read more →CADLCandel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights • On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer
Candel Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting key progress in its clinical trials and corporate developments. The company expects significant data readouts in 2024, particularly for its CAN-2409 trial in localized intermediate/high-risk prostate cancer. Candel also secured multiple FDA Fast Track Designations for its therapies, including CAN-3110 for recurrent high-grade glioma. However, Candel reported a net loss of $37.9 million for 2023, raising questions about its financial health as it plans for future developments.
Read more →CADLCandel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
Candel Therapeutics has announced an upcoming poster presentation at the AACR Annual Meeting, where they will unveil their second candidate developed through the enLIGHTEN Discovery Platform. This first-in-class multimodal immunotherapy candidate targets the induction of tertiary lymphoid structures, offering a novel approach for treating solid tumors. The presentation is scheduled for April 9, 2024, in San Diego, California, and signifies an acceleration of the program's timeline. The enLIGHTEN platform leverages advanced analytics and human biology to optimize immunotherapies.
Read more →CADL▲ +29.5%on this news
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
Candel Therapeutics announced that the FDA has granted Fast Track Designation to CAN-3110, an oncolytic viral immunotherapy candidate targeting recurrent high-grade glioma. This designation underscores the urgent need for more effective treatments in a field where conventional therapies have largely failed. Recent clinical trial data highlighted that a single injection of CAN-3110 showed promising improvements in median overall survival and a favorable safety profile, paving the way for further evaluations in upcoming studies.
Read more →CADLCandel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
Candel Therapeutics has announced multiple recent successes in its immunotherapy pipeline, and looks forward to six anticipated data readouts across various cancer platforms in 2024. The company received Fast Track Designation for its lead candidate CAN-2409 for treating non-small cell lung cancer and pancreatic cancer, bolstered by promising interim clinical data. Key trials are set to deliver further insights into the efficacy of CAN-2409 and CAN-3110 in difficult-to-treat cancers. Candel's innovative approaches and robust operational strategies aim to create substantial patient and stakeholder value.
Read more →CADL▲ +16.3%on this news
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
Candel Therapeutics announced that the FDA has granted Fast Track Designation for its investigational treatment CAN-2409 in patients with pancreatic ductal adenocarcinoma (PDAC). This designation follows promising interim data from a phase 2 clinical trial, which demonstrated a notable increase in overall survival rates compared to standard treatments. The company plans to release updated survival data in the second quarter of 2024, indicating ongoing progress in developing therapeutics for this challenging cancer type.
Read more →CADL▼ -8.2%on this news
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
Candel Therapeutics has announced a strategic restructuring to prioritize key projects, including CAN-3110 and the enLIGHTEN™ Discovery Platform, while reducing its workforce by about 50%. The company aims to shift resources toward crucial clinical readouts for CAN-2409 in various cancer types. Despite the layoffs, Candel anticipates extending its cash runway into Q4 2024, allowing for continued drug development and partnerships. Encouraging early data for CAN-3110 has been noted, suggesting potential positive outcomes for patients with recurrent high-grade glioma.
Read more →CADL▼ -13%on this news
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights • Initial survival data from phase 2 clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) showe
Candel Therapeutics has reported promising early survival data from its phase 2 trials of CAN-2409 in advanced non-small cell lung cancer (NSCLC) and borderline resectable pancreatic cancer. Initial data indicates a significant 71.4% survival rate at 36 months in the pancreatic cancer trial. For CAN-3110, a phase 1 trial showed nearly double the expected median overall survival in recurrent high-grade glioma. The company also introduced Alpha-201-macro1, a potential new agent in its viral immunotherapy lineup.
Read more →CADL▼ -21.5%on this news
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN Discovery Platform at SITC • The first experimental agent from the enLIGHTEN Discovery Platform is Alpha-201-macro1, an investigational viral immuno
Candel Therapeutics has presented preclinical data from its enLIGHTEN Discovery Platform at the SITC Annual Meeting. The data highlights the potential of Alpha-201-macro1, an investigational viral immunotherapy designed to enhance immune responses against tumors. Additionally, the platform’s advanced analytics aim to improve drug discovery by predicting effective payload combinations. Candel's novel approach may offer significant advantages in overcoming tumor resistance, although challenges related to systemic toxicity remain.
Read more →CADL▼ -21.5%on this news
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer • Initial positive interim data revealed notable improvements in p
Candel Therapeutics announced positive interim results from a Phase 2 clinical trial evaluating CAN-2409 in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). The trial showed an impressive overall survival rate of 71.4% at 36 months among patients treated with CAN-2409, compared to only 16.7% in the control group. Safety data indicated that the treatment was well tolerated, with no significant adverse effects reported. The findings highlight the potential of CAN-2409 to enhance survival and immune response in a challenging cancer landscape.
Read more →CADLCandel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110 • CAN-3110 is a first-in-class herpes
Candel Therapeutics has published findings in Nature regarding CAN-3110, a novel herpes simplex virus-1 oncolytic immunotherapy for recurrent high-grade glioma. The study indicates that treatment with CAN-3110 enhances immune activation and is associated with extended survival, demonstrating median overall survival rates significantly higher than historical controls. Positive responses were linked to pre-existing HSV-1 seropositivity. The publication highlights the potential of CAN-3110 as a promising therapeutic option in challenging glioma cases.
Read more →CADL▼ -9%on this news
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
Candel Therapeutics has announced that three abstracts have been accepted for poster presentations at the Society for Immunotherapy of Cancer's 38th Annual Meeting, scheduled for November 3-5, 2023. The presentations will cover initial survival data from ongoing trials of CAN-2409 in pancreatic cancer and new developments from their enLIGHTEN™ Discovery Platform. CAN-2409, the company's most advanced therapeutic candidate, aims to enhance immune response against various cancers, supported by favorable trial results to date. Further details will be available after the conference on Candel's website.
Read more →CADL▼ -10.7%on this newsshared move
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer o Initial data suggests 12-month survival is consistent with an increased tail on the ma
Candel Therapeutics has reported positive initial survival data from its Phase 2 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC). The trial showed that a significant number of patients, particularly those with low or negative PD-L1 status, experienced long-term survival, exceeding typical expectations for this difficult-to-treat population. No serious adverse events were reported, indicating a favorable safety profile for CAN-2409. The company expects to release topline overall survival data in Q2 2024.
Read more →CADLCandel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Candel Therapeutics, Inc. announced that its CEO, Dr. Paul Peter Tak, will present at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023, in New York City. The conference provides a platform for Candel to discuss its development of viral immunotherapies aimed at combating cancer. The company's lead candidates, CAN-2409 and CAN-3110, are currently in clinical trials for various cancer types, signaling ongoing advancements in their therapeutic offerings.
Read more →CADLCandel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Candel Therapeutics recently reported their financial results for the second quarter of 2023, emphasizing the potential of their oncology pipeline. Key highlights included positive clinical data for their CAN-3110 and CAN-2409 drug candidates, both receiving significant regulatory designations and showing promise in ongoing trials. However, the company also noted a substantial net loss compared to the previous year, alongside a drop in revenue from research and development services. Overall, Candel remains focused on advancing its viral immunotherapy programs with expected pivotal data releases in the coming quarters.
Read more →CADLCandel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Candel Therapeutics, Inc. announced its participation in the Canaccord Genuity 43rd Annual Growth Conference scheduled for August 10, 2023, where CEO Paul Peter Tak will engage in a fireside chat. The company specializes in developing viral immunotherapies for cancer treatment, with ongoing clinical trials for its lead product candidates in multiple indications, including non-small cell lung cancer and recurrent glioblastoma. A live webcast of the discussion will be available, reflecting Candel's commitment to transparent communication with stakeholders.
Read more →CADLCandel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024 • Based on forthcoming completion of patient
Candel Therapeutics has announced that it anticipates reporting topline overall survival data from its Phase 2 trial of CAN-2409 in patients with non-small cell lung cancer in the second quarter of 2024. The trial involves approximately 40 patients who have shown radiographic progression while on PD-(L)1 inhibitor therapy. The FDA has granted Fast Track designation for this investigational therapy, which is designed to improve survival outcomes in a challenging patient population. The company remains optimistic about the insights that could be gained from the upcoming data release.
Read more →CADL▲ +5.3%on this newsshared move
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors • Nicoletta Loggia, PhD, RPh, biopharma executive with more than two decades of technical expertis
Candel Therapeutics announced the appointment of Nicoletta Loggia, PhD, RPh, to its Board of Directors, effective June 7, 2023. Dr. Loggia brings over twenty years of experience in the biopharmaceutical industry, particularly in drug development and manufacturing. Her leadership is expected to be crucial as Candel approaches multiple data readouts and advances its late-stage oncology programs, which focus on viral immunotherapies for cancer treatment. The company is heading into an important phase, including a phase 3 clinical trial readout for localized prostate cancer next year.
Read more →CADL▲ +9.8%on this newsshared move
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Candel Therapeutics, a clinical-stage biopharmaceutical company, will participate in the 2023 Jefferies Healthcare Conference on June 7, 2023. CEO Paul Peter Tak is set to deliver a corporate presentation, highlighting the company's advancements in viral immunotherapies for cancer treatment. A live webcast of the presentation will be available on Candel's website, along with a replay for those unable to attend. Candel's strategy includes using genetically modified viruses to stimulate anti-tumor immune responses in patients.
Read more →CADL▼ -8.1%on this news
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Candel Therapeutics has announced promising results from its ongoing Phase 1 clinical trial of CAN-3110 for patients with recurrent high-grade glioma. The latest data indicate a median overall survival of 12.0 months in patients receiving the treatment, significantly exceeding the typical survival rates of 6 to 9 months associated with conventional therapies. CAN-3110 was well tolerated, and responses were observed in both injected and uninjected tumor lesions. Moving forward, the company plans to evaluate a repeat dosing regimen in arm C of the trial to further assess survival benefits.
Read more →CADL▼ -8.1%on this news
CAN-3110 a novel oncolytic virus engineered for enhanced activity and safety HSV-1 engineered for immunogenic potency and specificity ICP34.5-null viruses have shown safety, but replicate poorly CAN-3110: ICP34.5 express
CAN-3110, a novel oncolytic virus developed by Candel Therapeutics, has shown promising results in a Phase 1b clinical trial for recurrent high-grade glioma (rHGG). The trial indicated that the oncolytic HSV1 could potentially improve survival outcomes, with patients experiencing an overall survival rate of 11.8 months after treatment. Notably, some patients demonstrated durable responses for over 12 months. While the treatment was generally well-tolerated, serious adverse effects such as seizures and cerebral edema were noted, warranting further investigation.
Read more →CADLCandel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Candel Therapeutics reported its financial results for Q1 2023, highlighting continued advancement in its viral immunotherapy programs. The company received fast track designation from the FDA for its CAN-2409 therapy aimed at non-small cell lung cancer. They assured stakeholders of upcoming data presentations at major oncology meetings, including ASCO and ASGCT. Nevertheless, Candel faced a significant net loss and has paused new enrollments for one of its studies due to funding issues.
Read more →CADL▲ +15.4%on this news
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
Candel Therapeutics announced acceptance of an abstract detailing data from its phase 1 trial of CAN-3110 for recurrent high-grade glioma at the ASGCT 26th Annual Meeting. Additionally, they will present a trials-in-progress poster showcasing CAN-2409's efficacy combined with standard care for patients with stage III/IV non-small cell lung cancer at the ASCO 27th Annual Meeting. These events mark significant steps in Candel's ongoing clinical research and commitment to immunotherapy advancements. Detailed results from both presentations will be made available post-event on their website.
Read more →CADL▲ +19%on this news
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer • Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review o
Candel Therapeutics has received FDA fast track designation for CAN-2409, an investigational viral immunotherapy, aimed at treating stage III/IV non-small cell lung cancer (NSCLC) patients resistant to standard PD-(L)1 inhibitors. This designation allows for expedited development and review, addressing a significant unmet need in the treatment landscape. Preliminary phase 2 clinical trial data indicated a 77% disease control rate among participants, highlighting the potential of CAN-2409 in improving patient outcomes. Candel plans to present updated clinical trial data later in 2023.
Read more →CADLCandel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights • Expects to announce clinical trial data from multiple oncology programs in the second half of 2023
Candel Therapeutics has reported its fourth quarter and full year 2022 financial results, highlighting an extension of its cash runway into Q2 2024. The company anticipates announcements of clinical trial data from several oncology programs later this year. Significant clinical results were noted from trials involving CAN-2409 and CAN-3110, demonstrating promising anti-tumor activity in various cancer types. However, patient enrollment in the pancreatic cancer trial has been paused, and the reporting of prostate cancer trial results has been delayed until late 2024.
Read more →CADL▼ -6.2%on this news
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
Candel Therapeutics, a clinical stage biopharmaceutical company, announced its participation in the Guggenheim Healthcare Talks 2023 Oncology Day on February 8-9. CEO Paul Peter Tak will engage in a fireside chat, highlighting the company's advancements in viral immunotherapies for cancer treatment. The event will be held at the St. Regis Hotel in New York City, with a live webcast available for broader investor access.
Read more →CADLCandel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
Candel Therapeutics, Inc. (Nasdaq: CADL) will participate in the B. Riley Securities’ 3rd Annual Oncology Conference through a virtual fireside chat. CEO Paul Peter Tak is scheduled to present on January 19, 2023. A live webcast of the presentation will be available, with a replay accessible for up to 90 days. Candel is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to combat cancer.
Read more →CADL▼ -13%on this news
Research & Development Day Virtual |
Forward Looking Statements This Presentation contains forward-looking statements and information. All statements other than statements of historical facts contained in this Presentation, including express or implied statements regarding our strategy, future financial condition,
Read more →CADL▼ -13%on this news
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer • Updated data from the phase 2 clinical trial of CAN-2409
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer -Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 p
Read more →CADLCandel Therapeutics to Host Virtual R&D Day on
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022 -New clinical data to be presented from the Company's phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with late-stage non-small cell lung cancer. -Recent clinical data for CAN-31
Read more →CADLCandel Therapeutics to Host Virtual R&D Day on December 6, 2022
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with late-stage non-small cell lung cancer. Recent clinical data for CAN-3110 and CAN-2409 in high-grade glioma to be presented. Scientific r
Read more →CADLCandel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting • C
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting -CAN-3110 designed to limit replication and promote anti-tumor respon
Read more →CADLCandel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma •
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma -Combination of nivolumab and CAN-2409 delivered during neurosurger
Read more →CADL▲ +10.7%on this news· ran to +21% by day 3shared move
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights • Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Stu
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights -Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy
Read more →CADL▲ +9.7%on this newsshared move
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
NEEDHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced new clinical data will be presented in the upcoming 37th Annual Meeting of the Society fo
Read more →CADLCandel Therapeutics Upcoming Investor Conference Participation for November
NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will partic
Read more →CADLCandel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies in solid tumors Employs Candel’s enLIGHTEN™ Discovery Platform Both parties retain rights in respective programs and the rights to proceed towards clinical trials to study
Read more →CADLCandel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma
NEEDHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the European Medicines Agency (EMA) Committe
Read more →CADLCandel Therapeutics Announces Two Executive Leadership Appointments - Jason A. Amello joins Candel as Chief Financial Officer - Garrett Nichols, MD, MS joins Candel as Chief Medical Officer
Candel Therapeutics Announces Two Executive Leadership Appointments NEEDHAM, Mass., September 7, 2022 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherap
Read more →CADLCandel Therapeutics Upcoming Investor Conference Participation
NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Offi
Read more →CADLCandel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., August 5, 2022 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping
Read more →CADLCandel Therapeutics Appoints Three New Members to its Board of Directors Gary Nabel, MD, PhD, Chief Innovation Officer of OPKO and Chief Executive Officer, ModeX Therapeutics, Inc., an OPKO Health company Joseph Papa, Ch
Candel Therapeutics Appoints Three New Members to its Board of Directors NEEDHAM, Mass., August 1, 2022 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer wi
Read more →CADLBreakfast Event during ASCO 2022 Annual Meeting (NASDAQ: CADL) Tipping the balance in favor of the immune system to fight cancer Paul Peter Tak, MD, PhD, FMedSci President and Chief Executive Officer Candel Therapeutics,
Tipping the balance in favor of the immune system to fight cancer Paul Peter Tak, MD, PhD, FMedSci President and Chief Executive Officer Candel Therapeutics, Needham, MA 1 Forward-Looking Statements This Presentation contains forward-looking statements and information. All sta
Read more →CADL▲ +8.9%on this news· ran to +22% by day 1
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer • Disease control rat
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer -Disease control rate of 87.5 percent achieved in patients who were all progressing on
Read more →CADL▼ -6.2%on this news
Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Office
Read more →CADLCandel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights -Cash position bolstered through debt financing to support operations into the fourth quarter of 2023
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights -Cash position bolstered through debt financing to support operations into the fourth quarter of 2023- NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. (Cande
Read more →CADL▼ -5.5%on this news
Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for presentation at the upcoming Ameri
Read more →CADLCandel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights -Cash position remains strong to support operations into the fourth quarter of 2023
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights -Cash position remains strong to support operations into the fourth quarter of 2023- NEEDHAM, Mass., March 29, 2022 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. (Candel
Read more →CADLCandel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer
NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Seshu Tyagarajan Ph.D., RAC, has been named as the company’s Chief T
Read more →CADLCandel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank Additional capital extends cash runway into Q4 of 2023
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank NEEDHAM, Mass., March 1, 2022 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. (Nasdaq: CADL) (the Company or Candel ), a late clinical stage biopharmaceutical company developing
Read more →CADLCandel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer NEEDHAM, Mass., February 3, 2022 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today anno
Read more →CADL▼ -6.8%on this news
Candel Therapeutics to Present at Two Upcoming Investor Conferences
NEEDHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Offic
Read more →CADLCandel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409
Partnership for Accelerating Cancer Therapies to conduct extensive biomarker analysis for ongoing phase 2 clinical trial in non-small cell lung cancer Trial combines CAN-2409 with immune checkpoint inhibitor treatment after inadequate tumor response to initial checkpoint inhibit
Read more →CADLCandel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma
Data presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting Intra-tumoral administration of CAN-3110 elicited significant T-cell infiltration and expansion of T-cell repertoire in patients with recurrent high-grade glioma NEEDHAM, Mass., Nov. 12, 2021
Read more →CADLCandel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. ( Candel or the Company ) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel on
Read more →CADLCandel Therapeutics to Participate in Three Upcoming Investor Conferences
NEEDHAM, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Offic
Read more →CADLCandel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies
NEEDHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced its participation in upcoming medical and scientific conferences. Candel P
Read more →CADLCandel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer
NEEDHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that data on patient-reported tolerability assessment of intraprostatic in
Read more →CADLCandel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer
NEEDHAM, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced it has appointed Mace L. Rothenberg, MD, as a senior advisor to its Presid
Read more →CADL▼ -5.8%on this news
Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
NEEDHAM, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the Company will present novel biomarker data from the ongoing phase
Read more →CADLCandel Therapeutics Announces Participation in Upcoming Scientific Conferences Related to Oncolytic Viral Immunotherapies
NEEDHAM, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that its President and Chief Executive Officer, Paul Peter Tak, MD, PhD, F
Read more →CADLCandel Therapeutics Announces Presentations of Key Clinical Data at AdMeTech and European Association of Neuro-Oncology Conferences in September 2021
Dr. Scott E. Eggener to present safety data from phase 2 clinical trial of CAN-2409 in patients with localized, low to intermediate risk prostate cancer undergoing active surveillance at AdMeTech Foundation’s Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Ca
Read more →CADL▲ +12.6%on this newsshared move
Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights
Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., Sept. 8, 2021 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. ( the Company ) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic
Read more →CADL▲ +22.2%on this news· ran to +38% by day 1shared move
Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer
NEEDHAM, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that it has completed patient enrollment for its pivotal phase
Read more →CADL▼ -11.6%on this news
Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters Option
Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters Option NEEDHAM, Mass., August 17, 2021 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. ( Candel ), a late clinical stage biopharmaceutical company developing novel oncol
Read more →CADLCandel Therapeutics Announces Pricing of Initial Public Offering
NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the pricing of its initial public offering of 9,000,000 shares of common stock
Read more →CADLCandel Therapeutics Completes $28.7 Million Series B Financing
Proceeds to Accelerate Enrollment of Phase 3 Localized Prostate Cancer Clinical Trial and to Advance Late Stage High-Grade Glioma Clinical Program Candel to Expand Clinical Trials in Other Indications AUBURNDALE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Candel Therapeutics, a c
Read more →Competitive Position
How CADL ranks across every disease it competes inCompetitive Position is a premium feature
See how CADL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial